Aclarubicin: Difference between revisions

	WikiDoc Resources for Aclarubicin
Articles
Most recent articles on Aclarubicin Most cited articles on Aclarubicin Review articles on Aclarubicin Articles on Aclarubicin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Aclarubicin Images of Aclarubicin Photos of Aclarubicin Podcasts & MP3s on Aclarubicin Videos on Aclarubicin
Evidence Based Medicine
Cochrane Collaboration on Aclarubicin Bandolier on Aclarubicin TRIP on Aclarubicin
Clinical Trials
Ongoing Trials on Aclarubicin at Clinical Trials.gov Trial results on Aclarubicin Clinical Trials on Aclarubicin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Aclarubicin NICE Guidance on Aclarubicin NHS PRODIGY Guidance FDA on Aclarubicin CDC on Aclarubicin
Books
Books on Aclarubicin
News
Aclarubicin in the news Be alerted to news on Aclarubicin News trends on Aclarubicin
Commentary
Blogs on Aclarubicin
Definitions
Definitions of Aclarubicin
Patient Resources / Community
Patient resources on Aclarubicin Discussion groups on Aclarubicin Patient Handouts on Aclarubicin Directions to Hospitals Treating Aclarubicin Risk calculators and risk factors for Aclarubicin
Healthcare Provider Resources
Symptoms of Aclarubicin Causes & Risk Factors for Aclarubicin Diagnostic studies for Aclarubicin Treatment of Aclarubicin
Continuing Medical Education (CME)
CME Programs on Aclarubicin
International
Aclarubicin en Espanol Aclarubicin en Francais
Business
Aclarubicin in the Marketplace Patents on Aclarubicin
Experimental / Informatics
List of terms related to Aclarubicin

Aclarubicin
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	IV
ATC code	L01DB04 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name (1S,2S,4R)-Methyl 4-(((2S,5R,6R)-4-(dimethylamino)-5-(((1S,3R,4S)-3-hydroxy-5-methyl-4-(((2S,6R)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate;
CAS Number	57576-44-0 ;
PubChem CID	42474;
ChemSpider	1931 ;
UNII	74KXF8I502;
KEGG	D02756 ;
ChEBI	CHEBI:74619 ;
ChEMBL	ChEMBL1697719 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C42H53NO15
Molar mass	811.86 g/mol
3D model (JSmol)	Interactive image;
	SMILES CCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O;
	InChI InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3 ; Key:USZYSDMBJDPRIF-UHFFFAOYSA-N ;
(what is this?) (verify)

VisualWikitext

Latest revision as of 19:23, 6 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Aclarubicin (INN) or aclacinomycin A^[1] is an anthracycline drug^[2] that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin.

References

↑ Template:PubChem
↑ Jensen PB, Jensen PS, Demant EJ; et al. (October 1991). "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Res. 51 (19): 5093–9. PMID 1655244.

Template:Antineoplastic-drug-stub

[pubchem-1] Template:PubChem

[pmid1655244-2] Jensen PB, Jensen PS, Demant EJ; et al. (October 1991). "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Res. 51 (19): 5093–9. PMID 1655244.

[1]

[2]

@@ Line 1: / Line 1: @@
+{{Drugbox
+| Verifiedfields = changed
+| Watchedfields = changed
+| verifiedrevid = 477240878
+| IUPAC_name = (1''S'',2''S'',4''R'')-Methyl 4-(((2''S'',5''R'',6''R'')-4-(dimethylamino)-5-(((1''S'',3''R'',4''S'')-3-hydroxy-5-methyl-4-(((2''S'',6''R'')-6-methyl-5-oxotetrahydro-2''H''-pyran-2-yl)oxy)cyclohexyl)oxy)-6-methyltetrahydro-2''H''-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
+| image = Aclarubicin.png
+<!--Clinical data-->
+| tradename =
+| Drugs.com = {{drugs.com|international|aclarubicin}}
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
+| pregnancy_US = <!-- A / B            / C / D / X -->
+| pregnancy_category =
+| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
+| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
+| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
+| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
+| legal_status = Rx-only
+| routes_of_administration = [[Intravenous therapy|IV]]
+<!--Pharmacokinetic data-->
+| bioavailability =
+| protein_bound =
+| metabolism =
+| elimination_half-life =
+| excretion =
+<!--Identifiers-->
+| CAS_number_Ref = {{cascite|changed|??}}
+| CAS_number = 57576-44-0
+| ATC_prefix = L01
+| ATC_suffix = DB04
+| ATC_supplemental =
+| PubChem = 42474
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank =
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = 1931
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = 74KXF8I502
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D02756
+| ChEBI_Ref = {{ebicite|changed|EBI}}
+| ChEBI = 74619
+| ChEMBL_Ref = {{ebicite|changed|EBI}}
+| ChEMBL = 1697719
+<!--Chemical data-->
+| C=42 | H=53 | N=1 | O=15
+| molecular_weight = 811.86 g/mol
+| smiles = CCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O
+| InChI = 1/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3
+| InChIKey = USZYSDMBJDPRIF-UHFFFAOYAH
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChI = 1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChIKey = USZYSDMBJDPRIF-UHFFFAOYSA-N
+}}
 __NOTOC__
 {{SI}}
 {{CMG}}
+==Overview==
+'''Aclarubicin''' ([[International Nonproprietary Name|INN]]) or '''aclacinomycin A'''<ref name="pubchem">{{PubChem|451415}}</ref> is an [[anthracycline]] drug<ref name="pmid1655244">{{cite journal |author=Jensen PB, Jensen PS, Demant EJ, ''et al.'' |title=Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II |journal=Cancer Res. |volume=51 |issue=19 |pages=5093–9 |date=October 1991 |pmid=1655244 |doi= |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=1655244}}</ref> that is used in the treatment of [[cancer]]. Soil bacteria ''[[Streptomyces galilaeus]]'' can produce aclarubicin.
-{{SK}} Aclacinomycin A
+==References==
+{{reflist|2}}
-==Overview==
+{{Chemotherapeutic agents}}
-Aclarubicin is an anthracycline drug <ref name="pmid1655244">{{cite journal| author=Jensen PB, Jensen PS, Demant EJ, Friche E, Sørensen BS, Sehested M et al.| title=Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. | journal=Cancer Res | year= 1991 | volume= 51 | issue= 19 | pages= 5093-9 | pmid=1655244 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1655244  }} </ref> that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin.
-==References==
+[[Category:Anthracyclines]]
-{{Reflist|2}}
+[[Category:Topoisomerase inhibitors]]
-{{WH}}
-{{WS}}
-[[Category:Needs content]]
+{{antineoplastic-drug-stub}}

v t e Chemotherapeutic agents/Antineoplastic agents (L01)
Alkylating and alkylating-like agents	Nitrogen mustards: (Chlorambucil, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan, Bendamustine, Uramustine) Nitrosoureas:(Carmustine, Fotemustine, Lomustine, Streptozocin) Platinum (alkylating-like): (Carboplatin, Cisplatin, Oxaliplatin, Triplatin tetranitrate, Satraplatin) Alkyl sulfonates:(Busulfan, Treosulfan) Hydrazines:(Procarbazine, Dacarbazine, Temozolomide) Aziridines:(ThioTEPA)
Antimetabolites	Folic acid: (Aminopterin, Methotrexate, Pemetrexed, Raltitrexed). Purine:(Cladribine, Clofarabine, Fludarabine, Mercaptopurine, Pentostatin, Thioguanine) Pyrimidine:(Capecitabine, Cytarabine, Decitabine, Fluorouracil, Floxuridine, Gemcitabine)
Spindle poison/mitotic inhibitor	Taxane: (Docetaxel, Larotaxel, Paclitaxel). Vinca: (Vinblastine, Vincristine, Vindesine, Vinorelbine).
Cytotoxic/antitumor antibiotics	Anthracycline family: (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Pixantrone, Valrubicin) streptomyces (Actinomycin, Bleomycin, Mitomycin, Plicamycin) - Hydroxyurea
Topoisomerase inhibitors	Camptotheca: (Camptothecin, Topotecan, Irinotecan, Rubitecan), Podophyllum:(Etoposide, Teniposide)
CI monoclonal antibodies	Receptor tyrosine kinase (Cetuximab, Panitumumab, Trastuzumab) - CD20 (Rituximab, Tositumomab) - other (Alemtuzumab, Bevacizumab, Gemtuzumab)
Photosensitizers	Aminolevulinic acid, Methyl aminolevulinate, Porfimer sodium, Verteporfin
Tyrosine kinase inhibitors	Axitinib, Bosutinib, Cediranib, Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, Vandetanib
Cyclin-dependent kinase inhibitor	Seliciclib
Other	retinoids (Alitretinoin, Tretinoin), Fusion protein (Aflibercept) - Altretamine, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase (Pegaspargase), Bexarotene, Bortezomib, Celecoxib, Denileukin diftitox, Elesclomol, Estramustine, Irofulven, Ixabepilone, Masoprocol, Mitotane, Oblimersen, Testolactone, Tipifarnib, Trabectedin

Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	IV
ATC code	L01DB04 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name (1S,2S,4R)-Methyl 4-(((2S,5R,6R)-4-(dimethylamino)-5-(((1S,3R,4S)-3-hydroxy-5-methyl-4-(((2S,6R)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
CAS Number	57576-44-0^N
PubChem CID	42474
ChemSpider	1931^Y
UNII	74KXF8I502
KEGG	D02756^Y
ChEBI	CHEBI:74619^N
ChEMBL	ChEMBL1697719^N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₄₂H₅₃NO₁₅
Molar mass	811.86 g/mol
3D model (JSmol)	Interactive image
SMILES CCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O
InChI InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3^Y Key:USZYSDMBJDPRIF-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)

Aclarubicin: Difference between revisions

Latest revision as of 19:23, 6 April 2015

Overview

References

Navigation menu